“Through this strategic collaboration with Pfizer China, we look forward to fully integrating Sciwind Biosciences’ innovative scientific achievements with Pfizer China’s best-in-class commercialization capabilities to accelerate the commercialization of Ecnoglutide.” said Sciwind Biosciences.
More on Pfizer
- Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- Pfizer: Recovery Isn’t Over, Battered Valuation Still Discounts Its Turnaround Game
- CDC Deputy Director Ralph Abraham steps down
- Pharmaceutical tariffs still in play despite Supreme Court ruling